Eli Lilly and Company

LLY

Healthcare Drug Manufacturers General

Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024.

Revenue
+38.6%
EPS
+16.3%
Free cash flow
+21.8%
Total debt
+15.0%

Quarter to September 2026, against a year earlier

1,355.27 3.62 +0.27%
Market cap
$1.27T
P/E
43.9×
Fwd P/E FY26e
42.2×
Dividend yield
0.51%
F-score
7/9
ROIC
26.4%
Net debt / EBITDA
1.2×
Payout ratio
0.2×

Q3 2026 quarterly report Eli Lilly cut its full-year earnings guidance, one of four health-care companies to do so as government funding and drug pricing changed. Read it in the report

Latest quarter Q3 FY2026 · quarter to September 2026

Revenue growth has slowed two quarters running, from 55.5% to 38.6%.

Q3 FY2026 and the seven quarters before it
Quarter Revenue, $m Growth, % Op. margin, % EPS, $
Q3 FY26 24,397 38.6 36.5 7.22
Q2 FY26 22,974 47.7 39.1 7.94
Q1 FY26 19,799 55.5 45.0 8.26
Q4 FY25 19,291 42.5 41.5 7.39
Q3 FY25 17,601 53.9 43.9 6.21
Q2 FY25 15,558 37.6 44.1 6.29
Q1 FY25 12,729 45.2 29.0 3.06
Q4 FY24 13,533 44.7 34.8 4.88

Against the consensus: revenue beat by 10.4% ($24.4B v $22.1B); adjusted EPS beat by $2.10 ($7.48 v $5.38).

Growth is on the same quarter a year earlier, and EPS is diluted. Negative figures in brackets.

Outlook

FY2026 revenue: $91.0 billion–$92.0 billion

Company guidance, Q3 2026 earnings call.

Reports Feb 3, 2027 · Q4 FY26 · consensus EPS $11.05

All quarters →

Capital & Financial Ratios $m

Size
Market Cap 1,272,830
Revenue ttm 86,461
Net income ttm 27,580
Free cash flow ttm 19,661
Net debt Q 42,101
Valuation
P/E 43.9 (above 35: high)
Forward P/E FY26e 42.2 (above 35: high)
Price / sales 13.9 (above 10: high)
Forward P/S FY26e Powerpack
Price / FCF 55.1
Price / book 29.9 (above 6: high)
Financial health
Current ratio Q 1.4
Debt / equity Q 1.2
Interest coverage Q 0.0
Growth
Revenue growth FY26e +40.6% (at or above 10%: strong)
EPS growth FY26e +46.5% (at or above 15%: strong)
EPS growth FY27e +42.9% (at or above 15%: strong)
EPS growth, 5 yrs e +33.8% (at or above 15%: strong)
Insiders
Net sold 12m 16
Sells 12m 11
Buys 12m 0
Owned by insiders 4.9%

Green and red mark values outside typical ranges; (Q) is the latest quarter; e marks analysts’ estimates, FY26e the fiscal year ending in 2026; n/m is not meaningful, as a P/E on a loss. How we judge →

Compound annual growth

10y 5y 3y
Sales 12.56% 21.58% 31.69%
Cash Flow 18.95% 20.93% 30.38%
Earnings 23.96% 27.22% 48.96%
Book Value 6.16% 35.43% 35.04%

Valuation

The price implies free cash flow after share-based pay growing 21.6% a year for ten years. It grew 7.8% a year over the last ten.

Implied
21.6%
10 years, reported
7.8%
Open the model
P/E against its own 10 years 58.63%
10-year low 10-year high
P/S against its own 10 years 78.30%
10-year low 10-year high
P/B against its own 10 years 47.50%
10-year low 10-year high
EV/Sales against its own 10 years 78.33%
10-year low 10-year high
EV/FCF against its own 10 years 69.46%
10-year low 10-year high

Dividends raised every year since 2018

Yield
0.51%
Annual rate
6.92
Payout ratio
22.5%
Growth, 2018–26
+15.1%/yr
  1. 2.25 ’18
  2. 2.58 ’19 +15
  3. 2.96 ’20 +15
  4. 3.40 ’21 +15
  5. 3.92 ’22 +15
  6. 4.52 ’23 +15
  7. 5.20 ’24 +15
  8. 6.00 ’25 +15
  9. 6.92 ’26 +15
paid change on the year, % Powerpack

Analysts’ price targets Wall Street, collected weekly

Analyst price targets

Analysts’ consensus Wall Street average, updated each weekday

1.6
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 21,222 19,974 21,493 22,320 24,540 28,318 28,541 34,124 45,043 65,179 86,461 +13.3% 91,668 106,485 118,924 +22.2%
Gross margin, % 73.09 77.73 78.22 78.85 77.66 74.18 76.77 79.25 81.31 83.04 83.64 +10.0 pt
EBT 3,374 2,305 3,680 5,266 7,230 6,156 6,806 6,554 12,680 25,731 34,768 +25.3%
EBT margin, % 15.90 11.54 17.12 23.59 29.46 21.74 23.85 19.21 28.15 39.48 40.21 +23.6 pt
Net income 2,738 (204) 3,232 8,318 6,194 5,582 6,245 5,240 10,590 20,640 27,580 +25.2%
Per share, $
Per share, $ Revenue 20.05 18.99 20.91 23.97 27.04 31.22 31.65 37.91 50.01 72.64 96.94 +15.4%
Earnings 2.58 (0.19) 3.13 8.89 6.79 6.12 6.90 5.80 11.71 22.95 30.81 +27.5%
Cash flow 4.58 5.34 5.38 5.19 7.16 8.12 8.41 4.71 9.79 18.74 34.36 +16.9%
Capex (0.91) (1.02) (1.18) (1.11) (1.53) (1.44) (2.06) (3.83) (5.62) (8.74) (12.32) +28.6%
Free cash flow 3.67 4.31 4.20 4.08 5.63 6.68 6.36 0.88 4.18 10.00 22.04 +11.8%
Book value 13.30 11.09 10.61 2.90 6.42 10.09 11.95 12.07 15.85 29.57 45.15 +9.3%
Shares, m 1,058 1,052 1,028 931 908 907 902 900 901 897 894 (1.8%)
Valuation, ×
Valuation, × P/E 28.91 0.00 36.97 14.97 24.83 44.99 52.90 102.10 65.93 46.83 43.87 41.8
P/S 3.72 4.46 5.53 5.48 6.24 8.85 11.53 15.62 15.44 14.79 13.94 9.2
P/B 5.61 7.64 10.90 45.34 26.31 27.37 30.54 49.07 48.72 36.34 29.94 28.8
EV/Sales 3.83 4.56 5.62 6.07 6.77 9.30 12.02 16.14 16.02 15.34 14.51 9.6
EV/FCF 18.92 18.39 25.56 32.13 30.09 40.75 59.19 223.69 121.06 89.46 57.39 65.9
Cash, $m
Cash, $m Operating cash flow 4,851 5,616 5,525 4,837 6,500 7,366 7,586 4,240 8,818 16,813 30,645 +14.8%
Capex (964) (1,077) (1,211) (1,034) (1,388) (1,310) (1,854) (3,448) (5,058) (7,841) (10,984) +26.2%
Free cash flow 3,887 4,539 4,314 3,803 5,112 6,056 5,731 792 3,760 8,972 19,661 +9.7%
Balance, $m
Balance, $m Working capital 4,115 4,666 8,662 1,934 4,981 3,400 896 (1,566) 4,364 20,401 18,267 +19.5%
Net debt 4,266 5,613 2,890 13,000 12,914 11,438 12,526 15,393 25,259 33,600 42,101 +25.8%
Shareholders’ equity 14,081 11,668 10,909 2,699 5,825 9,155 10,775 10,864 14,272 26,535 40,271 +7.3%
Returns, %
Returns, % ROA 7.36 (0.49) 7.27 20.00 14.42 11.70 12.71 9.23 14.84 21.59 20.97 +14.2 pt
ROIC 11.11 7.25 16.01 19.80 20.20 19.29 19.12 15.37 20.39 27.34 26.42 +16.2 pt
ROE 19.10 (1.59) 28.63 122.26 145.32 74.52 62.67 48.43 84.26 101.16 86.02 +82.1 pt
People
People Employees 41,975 40,655 38,680 33,625 35,000 35,000 39,000 43,000 47,000 50,000 — +2.0%
Revenue/emp, $m 0.51 0.49 0.56 0.66 0.70 0.81 0.73 0.79 0.96 1.30 — +11.1%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated Nov 18, 2026

Business profile

Updated

Eli Lilly discovers, develops, manufactures and markets medicines for people. Founded in 1875 and headquartered in Indianapolis, it is led by Chair, President and Chief Executive Officer David Ricks. Lilly operates as one business segment: human pharmaceutical products.

Its cardiometabolic medicines include Mounjaro for type 2 diabetes and Zepbound for obesity or overweight with a weight-related condition. Zepbound is also used to treat moderate to severe obstructive sleep apnea in adults with obesity. Lilly sells insulin products and collaborates with Boehringer Ingelheim on Jardiance, which has diabetes, heart failure and chronic kidney disease indications.

Where the money comes from and where it goes Fiscal 2025

Fiscal 2025: revenue by segment, and margins
Reportable Segment 65,179 100.00%
Gross margin 83.04%
Operating margin 40.35%
Pre-tax margin 39.48%

Revenue by segment since 2010

Eli Lilly and Company vs peers in Drug Manufacturers General (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
LLY Eli Lilly and Company $1.27T 43.9× 42.2× FY26e +38.61% (above 0%: growing) +16.26% (above 0%: growing) +21.80% (above 0%: growing) 83.88% 36.52%
JNJ Johnson & Johnson $650.7B 40.5× 41.8× FY26e +5.86% (above 0%: growing) −95.75% (below 0%: shrinking) −21.44% (below 0%: shrinking) 68.12% 1.72% Compare
ABBV AbbVie Inc. $501.2B 48.8× 37.6× FY26e +10.32% (above 0%: growing) +2,270.00% (above 0%: growing) +9.97% (above 0%: growing) 75.38% 36.01% Compare
MRK Merck & Co., Inc. $328.6B 137× 105× FY26e +4.68% (above 0%: growing) −12.07% (below 0%: shrinking) −19.27% (below 0%: shrinking) 72.95% 31.90% Compare
NVS Novartis AG $277.7B 28.8× 24.0× FY26e +4.67% (above 0%: growing) −68.81% (below 0%: shrinking) −17.81% (below 0%: shrinking) 75.99% 12.26% Compare
AZN AstraZeneca PLC $272.1B 24.6× 24.2× FY26e +6.70% (above 0%: growing) +23.46% (above 0%: growing) +1.99% (above 0%: growing) 81.82% 27.07% Compare
AMGN Amgen Inc. $237.4B 25.2× 24.0× FY26e +8.45% (above 0%: growing) +19.39% (above 0%: growing) −13.98% (below 0%: shrinking) 73.10% 35.79% Compare
GILD Gilead Sciences, Inc. $207.8B — (loss-making) — (loss-making) +6.83% (above 0%: growing) −20.16% (below 0%: shrinking) +21.13% (above 0%: growing) 81.07% 41.71% Compare
PFE Pfizer Inc. $158.2B 38.8× 18.7× FY26e −0.43% (below 0%: shrinking) −9.68% (below 0%: shrinking) +20.02% (above 0%: growing) 75.71% 22.14% Compare
Median of peers $274.9B 38.8× 24.2× +6.28% −10.87% −5.99% 75.55% 29.49%

All 21 Drug Manufacturers General stocks →

From the latest earnings call

Updated

  • CEO David Ricks said more than 500,000 people had filled a Lilly prescription through the Medicare GLP-1 Bridge program since its July launch.
  • CFO Lucas Montarce said Lilly expects volume growth to more than offset lower net realized prices in 2027, alongside a full year of Medicare Bridge access.

Analyst rating changes each firm’s latest, last six months

Firm Date Action Rating Target Change
China Merchants Securities Nov 19, 2026 Downgrade Buy → Hold — —
Jefferies Nov 19, 2026 Target raised — 1,610.00 → 1,700.00 +5.59%
Leerink Partners Nov 6, 2026 Reiterated Buy 1,508.00 —
Scotiabank Nov 5, 2026 Target raised Outperform 1,300.00 → 1,605.00 +23.5%
Cantor Fitzgerald Nov 5, 2026 Target raised — 1,440.00 → 1,600.00 +11.1%
JPMorgan Nov 5, 2026 Target raised — 1,650.00 —
Goldman Sachs Nov 3, 2026 Target raised — 1,413.00 —
Morgan Stanley Nov 2, 2026 Reiterated Outperform — —
HSBC Nov 1, 2026 Target raised Underperform 940.00 —
Bank of America (BofA) Oct 20, 2026 Target raised Buy 1,341.00 → 1,397.00 +4.18%

Largest institutional holders 13F, quarter to Jun 30, 2026

Held by institutions 83.46%
Held by the ten largest 47.82%
Holder Shares Stake Change
LILLY ENDOWMENT INC 90.38m 9.60% −1.52m
Vanguard 82.81m 8.80% +180.78k
BlackRock 67.54m 7.17% +1.16m
PNC 51.32m 5.45% −6.19k
Capital Group 42.97m 4.56% −3.85m
State Street 36.22m 3.85% +605.75k
Fidelity (FMR) 28.46m 3.02% +2.12m
Geode Capital Management 20.31m 2.16% +118.99k
Morgan Stanley 16.23m 1.72% +788.94k
T. Rowe Price 13.96m 1.48% −1.06m
13F filings for the quarter to 30 June 2026: long positions in US-listed shares reported by managers with $100m or more, ~45 days after the quarter.

Pay and ownership Proxy statement filed Mar 20, 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 36.70m 75.19m 670.56
2024 29.24m 80.58m 478.17
2023 26.57m 120.87m 358.72
2022 21.40m 64.09m 222.94
2021 21.51m 75.71m 166.08

Ownership

Directors and executive officers, together less than 1%
Lilly Endowment Inc. (the Endowment) 9.80%
The Vanguard Group 8.60%
BlackRock, Inc. 6.80%
The PNC Financial Services Group, Inc. 5.40%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Eli Lilly and Company (LLY) Latest News

What happened

  1. Results Eli Lilly reported third-quarter revenue of $24.4 billion and raised its 2026 revenue guidance to $91 billion–$92 billion.
  2. Deal Eli Lilly agreed to acquire Calytrix Bio for up to $1.5 billion, including upfront and milestone payments.
  3. Deal Eli Lilly partnered with Hims & Hers to offer Zepbound and Foundayo through its digital platform at self-pay prices.
  4. Product Eli Lilly received China’s first approval for an oral GLP-1 weight-loss drug with orforglipron.
  5. Product Eli Lilly reported that Foundayo reduced sleep apnea severity in a Phase 3 trial and plans to seek FDA review by the end of 2026.
3 more headlines
All LLY news, as stories →

LLY metrics, ten years each

stockrow.com/LLY · Data as of Nov 18, 2026 · For information only; not investment advice. · © 2026 stockrow.com